Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE:EBS) reported Q2 2026 total revenues of $234.3 million, up 66% year over year, driven mainly by higher U.S. government sales of smallpox and other medical countermeasure (MCM) products. Adjusted net income was $30.9 million (up 134%) and adjusted EBITDA reached $96.5 million with a 41% margin. GAAP results showed a net loss of $180.2 million, largely due to a $191.3 million non-cash impairment on the NARCAN asset group, even as gross margin expanded to 50% and adjusted gross margin to 58%.
The company is implementing a restructuring, including about 90 role reductions and creating a new Growth organization, targeting approximately $40 million in annualized savings. Emergent also refinanced its term loan with a new $150 million facility, executed ACAM2000 and BAT contract modifications totaling over $117 million, secured new manufacturing partnerships, and obtained additional international approvals for ACAM2000.
Emergent BioSolutions (NYSE:EBS) underscores the growing need for biological threat preparedness as governments confront risks linked to geopolitical conflict, AI, synthetic biology and potential misuse of biological agents. The company highlights calls from European health officials and AI industry leaders for stronger safeguards, including screening of synthetic DNA and RNA orders.
Emergent points to recent anthrax-related events in Ukraine and Wyoming and notes a new NEJM Evidence study on the use of its CYFENDUS® anthrax vaccine for post-exposure prophylaxis in Wyoming. The release reiterates CYFENDUS®’s indication for adults 18–65 when used with antibacterial drugs and details key safety information, including contraindications, pregnancy risk, and common injection-site and systemic adverse reactions. Emergent positions itself as a long-standing partner to governments in delivering medical countermeasures against threats such as anthrax, smallpox, mpox and botulism.
Emergent BioSolutions (NYSE: EBS) announced it will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. Eastern time to discuss its second quarter 2026 financial results. Investors can access the call live via webcast on the company’s Investors page or by registering in advance for telephone participation to receive dial-in details, a unique passcode, and registrant ID. A replay of the call will also be available on the Investors page.
Emergent BioSolutions (NYSE:EBS) received a $52.7 million contract modification from ASPR/HHS to supply ACAM2000® smallpox and mpox vaccine, ancillaries, and diluent replacement lots for U.S. preparedness. Deliveries are expected to begin in June 2026 under an existing 10-year contract.
The announcement follows recent approvals of ACAM2000® for high-risk adults in Saudi Arabia and an expanded mpox indication in Singapore. The release also reiterates ACAM2000®’s indication and detailed safety information, including boxed warnings and common adverse reactions.
Emergent BioSolutions (NYSE:EBS) received a contract modification worth approximately $64.5 million from ASPR, part of U.S. HHS, under its existing 10-year agreement to supply BAT botulism antitoxin.
BAT treats symptomatic botulism in adults and pediatric patients; effectiveness is based on animal studies. Key warnings include hypersensitivity, infusion reactions, serum sickness, blood sugar test interference, and rare serious adverse reactions.
Emergent BioSolutions (NYSE:EBS) announced that senior management will participate in several upcoming investor conferences in late May and early June 2026.
Events include Goldman Sachs leveraged finance and global healthcare conferences, the Benchmark Healthcare House Call Virtual Investor Conference, and the Jefferies Global Healthcare Conference with webcast presentations and options for one-on-one meetings.
Emergent BioSolutions (NYSE:EBS) announced Saudi Food and Drug Authority approval of ACAM2000 [Smallpox and Mpox (Vaccinia) Vaccine, Live] for preventing smallpox and mpox in individuals at high risk of infection.
ACAM2000 is the first Emergent product licensed by SFDA and includes boxed warnings for serious potential complications.
Emergent BioSolutions (NYSE: EBS) reported Q1 2026 revenue of $156.1 million, net income of $6.8 million (4% margin) and adjusted EBITDA of $35.6 million (23% margin).
The company completed a $150 million term loan refinancing, secured strategic manufacturing partnerships including Substipharm, authorized up to $50 million of share repurchases, and won material government contracts including ~$140 million with Canada.
Emergent BioSolutions (NYSE:EBS) said Singapore’s Health Sciences Authority approved an expanded indication for ACAM2000 to include prevention of mpox in adults at high risk for mpox infection.
The approval is supported by existing human safety data and a controlled animal study showing vaccine effectiveness, and permits use during severe mpox outbreaks when alternatives are unavailable or contraindicated.
Emergent BioSolutions (NYSE: EBS) signed a multi-year manufacturing agreement with SAB Biotherapeutics to support development and manufacturing of SAB-142, a type 1 diabetes clinical candidate. The contract value is approximately $50 million, with $36 million contingent on regulatory approval and downstream milestones. Emergent will provide end-to-end process development, scale-up, analytical transfer, clinical manufacturing and potential commercial manufacture at its Winnipeg, Manitoba facility, which will act as the primary site for bulk intermediate and drug product production for SAB-142.